IL34 and HIV-1 infection: The resulting founder mice were crossed with immunodeficient NOG (NOD.Cg-PrkdcscidIl2rgtm1SugTg(CMV-IL-34)1/Jic) to generate NOGAPPKM670,671N/ IL-34 (NAIL) mouse, enabling studies of progressive HIV-1 infection in the setting of antiretroviral therapy (ART) and AD.